StockData
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc. (FULC) stock

FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.69−0.02 (-0.54%)

Close on Nov 20, 2026Market cap $281.54MP/E –Yield –

Fulcrum Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Fulcrum Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$66.14M. For fiscal 2025 it was -$60.38M. The highest annual figure on record is -$2.50M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$60.38M–
FY2024Dec 31, 2024-$2.50M–
FY2023Dec 31, 2023-$91.47M–
FY2022Dec 31, 2022-$99.01M–
FY2021Dec 31, 2021-$80.19M–
FY2020Dec 31, 2020-$55.00M–
FY2019Dec 31, 2019-$40.34M–
FY2018Dec 31, 2018-$31.54M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$16.15M–
Q1 FY2026Mar 31, 2026-$18.76M–
Q4 FY2025Dec 31, 2025-$16.96M–
Q3 FY2025Sep 30, 2025-$14.28M–
Q2 FY2025Jun 30, 2025-$13.89M-123.6%
Q1 FY2025Mar 31, 2025-$15.26M–
Q4 FY2024Dec 31, 2024-$16.99M–
Q3 FY2024Sep 30, 2024-$19.09M–
Q2 FY2024Jun 30, 2024$58.90M–
Q1 FY2024Mar 31, 2024-$25.31M–
Q4 FY2023Dec 31, 2023-$23.24M–
Q3 FY2023Sep 30, 2023-$22.97M–
Q2 FY2023Jun 30, 2023-$20.98M–
Q1 FY2023Mar 31, 2023-$24.29M–
Q4 FY2022Dec 31, 2022-$19.81M–
Q3 FY2022Sep 30, 2022-$28.17M–
Q2 FY2022Jun 30, 2022-$28.68M–
Q1 FY2022Mar 31, 2022-$22.35M–
Q4 FY2021Dec 31, 2021-$22.38M–
Q3 FY2021Sep 30, 2021-$22.94M–
Q2 FY2021Jun 30, 2021-$18.39M–
Q1 FY2021Mar 31, 2021-$16.49M–
Q4 FY2020Dec 31, 2020-$20.30M–
Q3 FY2020Sep 30, 2020-$4.60M–
Q2 FY2020Jun 30, 2020-$14.33M–
Q1 FY2020Mar 31, 2020-$15.77M–
Q4 FY2019Dec 31, 2019-$4.60M–
Q3 FY2019Sep 30, 2019-$13.23M–
Q2 FY2019Jun 30, 2019-$12.30M–
Q1 FY2019Mar 31, 2019-$10.21M–
Q4 FY2018Dec 31, 2018-$9.87M–
Q3 FY2018Sep 30, 2018-$5.05M–

More Fulcrum Therapeutics figures

See a number that looks wrong?